China Pharma Holdings (CPHI) Net Cash Flow Growth (3y) (2013 - 2026)
China Pharma Holdings (CPHI) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | China Pharma Holdings | 42.14 Mn | 41.84 Mn | 83,566.00 | 34.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.80% |
| Dec 31, 2025 | 47.71% |
| Sep 30, 2025 | -329.73% |
| Jun 30, 2025 | 29.77% |
| Mar 31, 2025 | 43.48% |
| Dec 31, 2024 | -26.13% |
| Sep 30, 2024 | 71.19% |
| Jun 30, 2024 | -27.11% |
| Mar 31, 2024 | -11.07% |
| Dec 31, 2023 | -81.50% |
| Sep 30, 2023 | 31.42% |
| Jun 30, 2023 | -28.75% |
| Mar 31, 2023 | -8.55% |
| Dec 31, 2022 | 8.02% |
| Sep 30, 2022 | 82.09% |
| Jun 30, 2022 | -90.62% |
| Mar 31, 2022 | -26.01% |
| Dec 31, 2021 | 55.09% |
| Sep 30, 2021 | -0.67% |
| Jun 30, 2021 | 69.59% |